Double-platinum chemotherapy combined with etoposide in metastatic brain tumor from small cell lung carcinoma.
The platinum-based chemotherapeutic agents, such as cisplatin (CDDP) and carboplatin (CBDCA), are effective for small cell lung carcinoma (SCLC). However, high dose treatment of these agents required for advanced-stage SCLC is often associated with severe toxicity. The authors used combination of lower doses of both cisplatin and carboplatin combined with etoposide (VP-16) to minimize side effects of these agents. This goal was accomplished by utilizing the facts that each agent has its own toxicity that can be controlled individually. Two patients (60- and 71-year old men) with multiple metastatic brain tumors from SCLC were treated by our chemotherapeutic regimen. After fourth chemotherapy, remarkable shrinking of brain masses was associated with significant decrease the size of original lung lesions in both cases. The two patients were discharged without any side effects of the treatment, and neurological deficits subsided in both cases. Each course provided the following schedules: carboplatin 200 mg/m2 x 1 day, cisplatin 25 mg/m2 x 2 days (intravenous administration), and etoposide 25 mg oral x 14 days. After second chemotherapy, the patient of Case 1 was irradiated to both brain and chest lesions, and only to brain in Case 2. The authors concluded from our two cases that the combination of these agents extremely effective to treat this malignancy with less toxicity. We named this double platinum chemotherapy as 'PEC', abbreviated from cisplatin, etoposide, and carboplatin. m
Yamada
Shoko M
SM
Department of Neurosurgery, Mizonokuchi Hospital, Teikyo University, Japan. yamadasm@med.kochi-u.ac.jp
Yamada
Shokei
S
Takahashi
Hiroshi
H
Teramoto
Akira
A
Nakayama
Hitoshi
H
D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D024221:Antineoplastic Protocols; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin
Am J Clin Oncol. 1997 Oct;20(5):500-4
9345336
Am J Clin Oncol. 1997 Apr;20(2):125-7
9124183
J Clin Oncol. 2001 Aug 1;19(15):3532-8
11481360
Med Oncol. 1998 Apr;15(1):66-9
9643534
Semin Oncol. 2001 Jun;28(3 Suppl 10):15-8
11510029
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1527-31
387223
Cancer Metastasis Rev. 2001;20(1-2):13-25
11831641
J Clin Oncol. 1987 Feb;5(2):185-9
3027268
J Chemother. 1995 Oct;7(5):460-2
8596133
J Clin Oncol. 1989 Jul;7(7):916-22
2544685
N Engl J Med. 1999 Aug 12;341(7):476-84
10441603
Acta Radiol Oncol. 1985 Nov-Dec;24(6):475-9
3006436
J Clin Oncol. 1989 May;7(5):651-61
2651580
J Clin Oncol. 1985 Nov;3(11):1471-7
2997406
J Clin Oncol. 1994 Nov;12(11):2327-32
7964948
J Clin Oncol. 1994 Oct;12(10):2022-34
7931470
Respir Med. 2001 Mar;95(3):235-6
11266242
Am J Clin Oncol. 1996 Apr;19(2):193-8
8610649
Crit Rev Oncol Hematol. 2001 Jan;37(1):61-7
11164720
J Natl Cancer Inst. 1995 Feb 1;87(3):183-90
7707405